Swine flu and antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Barlow, Gavin D ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Influenza; Lower respiratory tract infections; Pneumonia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEFUROXIME; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; MOXIFLOXACIN; OSELTAMIVIR; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; GROUP A STREPTOCOCCAL INFECTION; HAEMOPHILUS INFLUENZAE; HEALTH CARE QUALITY; HUMAN; INFLUENZA; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SECONDARY INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SWINE INFLUENZA VIRUS; UNITED KINGDOM; ANIMAL; BACTERIAL INFECTION; CASE MANAGEMENT; CROSS INFECTION; DRUG UTILIZATION; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CASE MANAGEMENT; CROSS INFECTION; DRUG UTILIZATION; GREAT BRITAIN; GUIDELINES AS TOPIC; HUMANS; INFLUENZA, HUMAN; RESPIRATORY TRACT INFECTIONS;

EID: 73949147436     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp313     Document Type: Article

References (31)

1. Chowell G, Bertozzi SM, Colchero MA et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; doi:10.1056/NEJMoa0904023.
2. British Infection Society, British Thoracic Society and Health Protection Agency in collaboration with the Department of Health. Clinical management of patients with an influenza-like illness during an influenza pandemic. Thorax 2007; 62 Suppl 1: 1-46.
3. Department of Health. Swine flu clinical package. 16 June 2009. www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/DH_100941 (28 July 2009, date last accessed).
4. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82.
5. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007; 62: 253-99.
6. Capelastegui A, España PP, Quintana JM et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Resp J 2006; 27: 151-7.
7. Man SY, Lee N, Ip M et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007; 62: 348-53.
8. Barlow G, Nathwani D, Myers E et al. Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia. J Antimicrob Chemother 2008; 61: 442-51.
9. Howell MD, Donnino MW, Talmor D et al. Performance of severity of illness scoring systems in emergency department patients with infection. Acad Emerg Med 2007; 14: 709-14.
10. Nathwani D, Morgan M, Masterton RG et al. on behalf of the British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008; 61: 976-94.
11. Challen K, Bright J, Bentley A et al. Physiological-social score (PMEWS) vs. CURB-65 to triage pandemic influenza: a comparative validation study using community-acquired pneumonia as a proxy. BMC Health Serv Res 2007; 7: 33.
12. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 Suppl 4: iv1-64.
13. Ellis C, McEwen R. Who should receive Tamiflu for swine flu? BMJ 2009; 339: b2698.
14. Dubberke ER, Reske KA, Yan Y et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45: 1543-9.
15. Monnet DL, MacKenzie FM, López-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-4.
16. Department of Health. Clostridium difficile infection: how to deal with the problem. www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/DH_093220 (28 July 2009, date last accessed).
17. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-80.
18. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=1 0938 (28 July 2009, date last accessed).
19. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009; 9: 281-90.
20. Lim WS, Macfarlane JT, Boswell TCJ et al. Study of communityacquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296-301.
21. Kallen AJ, Brunkard J, Moore Z et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53: 358-65.
22. Niederman MS, Anzueto A, Sethi S et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 2006; 100: 1781-90.
23. van der Eerden MM, Vlaspolder F, de Graaff CS et al. Comparison between pathogen directed antibiotic treatment and empirical broad-spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672-8.
24. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29: 44-50.
25. Nasrin D, Collignon PJ, Roberts L et al. Effect of b-lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. BMJ 2002; 324: 28-30.
26. el Moussaoui R, de Borgie CAJM, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332: 1355.
27. Oosterheert JJ, Bonten MJM, Schneider MME et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333: 1193.
28. Halm EA, Fine MJ, Kapoor WN et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-84.
29. Rempe S, Hayden JM, Robbins RA et al. Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets 2007; 7: 232-6.
30. Waterer GW. Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. Curr Opin Infect Dis 2005; 18: 157-63.
31. Health Protection Agency. Antimicrobial Resistance and Prescribing in England, Wales and Northern Ireland, 2008. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/12167980807 55 (28 July 2009, date last accessed).